Tibet Aim Pharm Inc (002826) — Capital Reinvestment Ratio
Latest as of September 2025:
0.03x
Tibet Aim Pharm Inc (002826) has a Capital Reinvestment Ratio of 0.03x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥87.55 Million) in capital expenditures (CN¥3.02 Million). See free cash flow generation of Tibet Aim Pharm Inc to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.03x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥87.55 Million
CNY
Capital Expenditures
CN¥3.02 Million
CNY
Data as of
Sep 2025
Most recent filing
Tibet Aim Pharm Inc Capital Reinvestment Ratio (2013–2025)
This chart tracks Tibet Aim Pharm Inc's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for Tibet Aim Pharm Inc (2013–2025)
Year-by-year Capital Reinvestment Ratio for Tibet Aim Pharm Inc from 2013 to 2025. For live market cap and broader valuation context, see Tibet Aim Pharm Inc market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.07x | CN¥123.72 Million | CN¥8.50 Million | ▼ -37.4% |
| 2024 | 0.11x | CN¥111.57 Million | CN¥12.24 Million | ▲ +475.7% |
| 2023 | 0.02x | CN¥166.88 Million | CN¥3.18 Million | ▼ -59.2% |
| 2022 | 0.05x | CN¥68.45 Million | CN¥3.20 Million | ▼ -79.7% |
| 2021 | 0.23x | CN¥109.52 Million | CN¥25.20 Million | ▼ -39.1% |
| 2020 | 0.38x | CN¥101.74 Million | CN¥38.43 Million | ▼ -86.9% |
| 2019 | 2.88x | CN¥59.20 Million | CN¥170.45 Million | ▼ -43.4% |
| 2018 | 5.09x | CN¥13.31 Million | CN¥67.72 Million | ▲ +426.8% |
| 2017 | 0.97x | CN¥77.29 Million | CN¥74.62 Million | ▲ +198.0% |
| 2016 | 0.32x | CN¥57.18 Million | CN¥18.52 Million | ▼ -98.4% |
| 2014 | 20.66x | CN¥2.18 Million | CN¥45.12 Million | ▲ +3671.3% |
| 2013 | 0.55x | CN¥52.24 Million | CN¥28.62 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow